publication date: Nov. 8, 2019

Texas votes to keep CPRIT open with another $3 billion in state funding

By Matthew Bin Han Ong

Texans have approved an additional $3 billion in state funds for the Cancer Prevention and Research Institute of Texas, extending the institute’s operations well past its sunset date in 2023.

The push to renew CPRIT was put to the ballot as Proposition 6, one of 10 statewide amendments to the constitution that were considered during the general election Nov. 5. Only Proposition 1—which would allow municipal court judges to serve multiple municipalities at the same time—was not approved.

Proposition 6 passed 64%-36%, authorizing another $3 billion in general obligation bonds for CPRIT, and doubling the maximum amount of bonds the legislature can issue on behalf of the institute to a total of $6 billion.

Founded in 2007, CPRIT was initially authorized at $3 billion in bonds to fund research and prevention programs throughout Texas.

“We are grateful to Texas voters for supporting CPRIT’s renewal and to the Texas Legislature for its profound vision in enabling this policy,” Peter Pisters, president of MD Anderson Cancer Center, said to The Cancer Letter. “This continued investment advances discoveries in cancer research, treatment and prevention, and strengthens our fight to end cancer.”

According to Proposition 6, the Texas Public Finance Authority may issue  up to $300 million in bonds a year to fund CPRIT. This means that, as long as the institute is funded annually in accordance with the allocation set out in the amendment, CPRIT’s operational lifespan is extended for at least another 10 years.

“The renewal of CPRIT will help us further decrease the burden of cancer across the state of Texas … Continue reading Texas votes to keep CPRIT open with another $3 billion in state funding

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.